Alejandro García Pérez | GlucoModicum: What clinical trial results support the accuracy of GlucoModicum's non-invasive glucose monitoring system?
00:09:30 - 00:10:05
Other snippets from this talk
Summary of the clip:
What clinical trial results support the accuracy of GlucoModicum's non-invasive glucose monitoring system?
GlucoModicum has conducted extensive clinical trials to validate the accuracy of their non-invasive glucose monitoring system. The latest trial involved over 600 participants, divided into different groups to test variations of the device. The speaker highlights the positive results obtained from their best-performing system.
The accuracy of the system is measured using Mean Absolute Relative Difference (MARD), a standard parameter in the glucose monitoring industry. The speaker reports that with one-time blood glucose calibration, their system has achieved MARD levels comparable to industry standards. This indicates a high degree of accuracy in glucose measurement.
Furthermore, the speaker mentions that they are rapidly approaching the required accuracy levels for real-time, no-calibration measurements. This suggests that the system is progressing towards a calibration-free operation, which would further enhance its convenience and usability. The speaker also mentions plans to submit these clinical trial reports to the Finnish regulatory agency, Fimea.
In this short video, you can learn:
* The scale and scope of GlucoModicum's clinical trials.
* The accuracy metrics (MARD) achieved by their system with one-time calibration.
* The progress towards real-time, no-calibration glucose monitoring.
📋 **Clip Abstract** This segment presents the clinical trial results of GlucoModicum's non-invasive glucose monitoring system, highlighting the accuracy achieved with one-time calibration and the progress towards real-time, calibration-free operation. It emphasizes the use of MARD as a key performance indicator.
🔗 Link in comments 👇
#NonInvasiveGlucoseMonitoring, #MARDAccuracy, #BloodGlucoseCalibration, #CalibrationFreeMonitoring, #MedicalDevices, #Biosensors
This is a highlight of the presentation:
Accurate and needle-free Continuous glucose monitoring enabled by MHD technology
More Highlights from the same talk.
00:07:52 - 00:08:37
How does magneto-hydrodynamics enable non-invasive glucose monitoring?
How does magneto-hydrodynamics enable non-invasive glucose monitoring?
The core technology enabling GlucoModicum's non-invasive glucose monitoring is based on magneto-hydrodynamics. This method allows for the extraction of dermal interstitial fluid from the skin without the use of needles. The speaker emphasizes that accessing a reliable sample is the primary challenge in non-invasive glucose monitoring, and their technology addresses this directly.
The technology, invented at the University of Helsinki's Department of Physics, applies Lorentz force to the interstitial fluid. This application of the right-hand rule facilitates efficient extraction of the fluid with minimal impact on the skin, resulting in a painless process. The speaker highlights the simplicity of the solution despite the complex name.
The technology has undergone thorough investigation since 2018, with multiple publications in prestigious journals and global patent protection. The speaker offers to provide more details about the technology's workings after the presentation, indicating a willingness to engage in deeper technical discussions.
In this short video, you can learn:
* The fundamental principle behind GlucoModicum's non-invasive glucose extraction.
* How magneto-hydrodynamics is applied to extract interstitial fluid.
* The validation and patent status of the core technology.
📋 **Clip Abstract** This segment explains the core technology behind GlucoModicum's non-invasive glucose monitoring system, focusing on the use of magneto-hydrodynamics to extract interstitial fluid. It highlights the technology's simplicity, validation, and patent protection.
🔗 Link in comments 👇
#MagnetoHydrodynamics, #InterstitialFluidExtraction, #LorentzForce, #NonInvasiveMonitoring, #MedicalDevices, #BioSensing
00:05:31 - 00:05:48
What are the environmental and usage limitations of current CGM devices?
What are the environmental and usage limitations of current CGM devices?
Current Continuous Glucose Monitoring (CGM) devices are primarily disposable, requiring replacement every 10-15 days. This disposability contributes significantly to their high cost, as each device contains electronics, plastics, and biosensors that are discarded after a short period. The speaker points out the environmental impact of this disposable nature.
Furthermore, the speaker notes that users often try to maximize the usage duration of these expensive devices. This extended wear time can lead to skin reactions due to prolonged contact with the same spot on the body. The speaker highlights this as a significant challenge for many users, indicating a trade-off between cost-effectiveness and skin health.
The speaker also mentions that for individuals who do not require constant glucose monitoring, current CGMs generate excessive data. This is particularly relevant for those in pre-diabetes or at risk, who may only need monitoring for a few days to understand their condition. The speaker suggests that these users end up paying for data that is not clinically relevant to them.
In this short video, you can learn:
* The disposable nature of current CGM devices and its impact on cost.
* The skin irritation issues associated with prolonged CGM use.
* The problem of excessive data generation for certain user groups.
📋 **Clip Abstract** This segment discusses the limitations of current CGM devices, focusing on their disposable nature, the resulting environmental impact and cost, and the skin irritation issues associated with prolonged use. It also touches on the problem of excessive data generation for users who do not require constant monitoring.
🔗 Link in comments 👇
#DisposableElectronics, #Biosensors, #Biocompatibility, #MedicalWaste, #MedTech, #WearableTech